Cardiology — MCQs

Cardiology Indian Medical PG Practice Questions and MCQs

Question 1411: A 55-year-old woman with a history of rheumatic fever presents with exertional dyspnea and palpitations. On examination, there is a mid-diastolic murmur at the apex. Which valvular abnormality is most likely present?

A. Aortic stenosis
B. Mitral stenosis (Correct Answer)
C. Tricuspid regurgitation
D. Pulmonic stenosis

Explanation: ***Mitral stenosis*** - A history of **rheumatic fever** is a common cause of mitral stenosis [1], leading to thickening and calcification of the mitral valve. - The classic auscultatory finding in mitral stenosis is a **mid-diastolic murmur heard best at the apex** [1]. Exertional dyspnea and palpitations are symptoms of left atrial enlargement and pulmonary congestion [1]. *Aortic stenosis* - While aortic stenosis can cause exertional dyspnea and palpitations, its characteristic murmur is a **systolic ejection murmur** heard best at the right upper sternal border, often radiating to the carotid arteries. - Aortic stenosis is more commonly associated with **degenerative calcification** in older adults [2] or a bicuspid aortic valve, rather than rheumatic fever as the primary cause in this age group, though rheumatic fever can affect this valve too. *Tricuspid regurgitation* - This condition presents with a **holosystolic murmur** best heard at the left lower sternal border, which typically **intensifies with inspiration**. - While rheumatic fever can affect the tricuspid valve, isolated tricuspid regurgitation is less common as the primary finding with these symptoms and a mid-diastolic murmur is not characteristic. *Pulmonic stenosis* - Pulmonic stenosis is characterized by a **systolic ejection murmur** heard best at the left upper sternal border, often associated with a thrill. - Symptoms like exertional dyspnea and palpitations can occur, but it is less commonly caused by rheumatic fever and does not produce a mid-diastolic murmur at the apex.

Question 1412: What is the first-line treatment for a patient diagnosed with symptomatic bradycardia?

A. Atropine (Correct Answer)
B. Beta-blockers
C. Pacemaker
D. Digoxin

Explanation: ***Atropine*** - **Atropine** is the **first-line pharmacological agent** for symptomatic bradycardia because it blocks the action of acetylcholine at muscarinic receptors, thereby enhancing **sinoatrial (SA) node automaticity** and **atrioventricular (AV) node conduction**. - It rapidly increases **heart rate** and improves symptoms such as hypotension and syncope in patients with bradycardia attributable to increased vagal tone or AV nodal block. *Beta-blockers* - **Beta-blockers** decrease heart rate and slow AV nodal conduction [2], which could **worsen bradycardia**, making them contraindicated in acute symptomatic bradycardia [4] unless used to treat an underlying tachyarrhythmia, which is not the case here. - Their primary use is for conditions like **hypertension**, **angina**, and **tachyarrhythmias**, not initially for bradycardia. *Pacemaker* - A **pacemaker** is considered for **symptomatic bradycardia** if **atropine** and other temporary measures (like transcutaneous pacing) fail, or in cases of ** Mobitz II AV block**, **complete heart block**, or **sick sinus syndrome** with persistent symptoms [1]. - It is a **definitive treatment** for persistent and severe bradycardia but not the first-line pharmacological intervention. *Digoxin* - **Digoxin** is a **cardiac glycoside** that slows the heart rate by increasing vagal tone and prolonging AV nodal refractory period, making it **contraindicated in symptomatic bradycardia** as it would further depress heart rate and conduction [3]. - Its primary uses are in conditions like **heart failure** and **atrial fibrillation with rapid ventricular response** where slowing the heart rate is desired, but not in existing bradycardia.

Question 1413: A patient with a long-standing history of hypertension presents with a sudden onset of severe chest pain radiating to the back. Imaging reveals a dissection in the aorta. Which part is most commonly affected?

A. Ascending aorta (Correct Answer)
B. Aortic arch
C. Descending aorta
D. Abdominal aorta

Explanation: ### Ascending aorta - The **ascending aorta** is the most common site for **aortic dissection**, particularly in patients with **hypertension**, due to high shear stress and vulnerability at this location [1]. - Dissections in the ascending aorta (Type A dissections) are **medical emergencies** due to the risk of rupture, cardiac tamponade, and organ ischemia. *Aortic arch* - While dissections can involve the **aortic arch**, they are less common as the primary site of origin compared to the ascending aorta. - Dissections originating here are often extensions of ascending aortic dissections (Type A), or less commonly, arise primarily from the arch, presenting complex surgical challenges due to major vessel involvement. *Descending aorta* - Dissections originating in the descending aorta (Type B dissections), typically **distal to the left subclavian artery**, are less common than Type A dissections [1]. - While they can be severe, they are often managed medically unless complications like malperfusion or rapid expansion occur. *Abdominal aorta* - Dissections originating primarily in the **abdominal aorta** are relatively rare compared to those in the thoracic aorta. - Abdominal aortic pathology is more commonly associated with **aneurysms**, which are dilations, rather than dissections, although dissections can extend into this segment [1].

Question 1414: In a clinical evaluation of a hypertensive patient, the most likely cause of an observed fourth heart sound (S4) is:

A. Ventricular hypertrophy (Correct Answer)
B. Mitral valve prolapse
C. Aortic stenosis
D. Pericarditis

Explanation: ***Ventricular hypertrophy*** - A **fourth heart sound (S4)** is typically caused by **atrial contraction** against a stiff, non-compliant ventricle [1], often seen in **ventricular hypertrophy** due to chronic hypertension. - The S4 signifies **diastolic dysfunction**, where the ventricle has difficulty relaxing and filling properly [1]. *Mitral valve prolapse* - **Mitral valve prolapse** is characterized by a **mid-systolic click** and a late-systolic murmur, not an S4. - It involves the **leaflet bulging** into the left atrium during systole, usually not leading to ventricular stiffness. *Aortic stenosis* - **Aortic stenosis** typically presents with a **systolic ejection murmur** that radiates to the carotids, often with a diminished S2. - While severe aortic stenosis can lead to left ventricular hypertrophy and thus an S4, the **primary cause** of S4 is the hypertrophy itself, not the stenosis directly. *Pericarditis* - **Pericarditis** often causes a **pericardial friction rub** and chest pain, and may lead to distant heart sounds in the case of effusions. - It does not directly cause an S4, which is related to ventricular stiffness during filling.

Question 1415: A 60-year-old male with a history of myocardial infarction presents with new-onset heart failure symptoms. An echocardiogram shows severe mitral regurgitation. What is the most appropriate management option for this patient?

A. Mitral valve repair to improve symptoms and prevent further cardiac deterioration. (Correct Answer)
B. Medical management to stabilize symptoms.
C. Observation with repeat echocardiogram in 3 months.
D. Initiate anticoagulation to prevent thromboembolism.

Explanation: ***Mitral valve repair to improve symptoms and prevent further cardiac deterioration.*** - In a patient with a history of **myocardial infarction** and new-onset **severe mitral regurgitation (MR)** leading to heart failure, surgical intervention (repair or replacement) is often indicated to relieve symptoms and improve long-term outcomes [1]. - Repair is generally preferred over replacement when feasible, as it often preserves ventricular function better and avoids the need for lifelong anticoagulation in most cases [1]. *Medical management to stabilize symptoms.* - While initial medical management is crucial for stabilizing heart failure symptoms, it does not address the underlying **severe structural problem** of mitral regurgitation, which will likely lead to continued progressive cardiac deterioration [1]. - Medical therapy alone is typically insufficient for severe, symptomatic MR, and can only delay the inevitable need for surgical correction. *Observation with repeat echocardiogram in 3 months.* - Given the **severe mitral regurgitation** and **symptomatic heart failure**, observation is not an appropriate initial strategy as the patient's condition is likely to worsen without intervention. - This approach might be considered for asymptomatic or mild-to-moderate MR, but not in this severe, symptomatic case. *Initiate anticoagulation to prevent thromboembolism.* - While **atrial fibrillation** (a risk factor for thromboembolism) can be associated with severe mitral valve disease, anticoagulation is not the primary treatment for severe MR itself. - Anticoagulation is indicated if the patient has **atrial fibrillation** or a **mechanical prosthetic valve** after replacement, but it doesn't address the cause of heart failure in this scenario.

Question 1416: In a patient experiencing heart failure, enlargement of which vein may be visible as a sign of increased central venous pressure?

A. Cephalic vein
B. Basilic vein
C. External jugular vein (Correct Answer)
D. Internal jugular vein

Explanation: ***External jugular vein*** - The **external jugular vein** is often visible externally when distended due to elevated **central venous pressure** in heart failure. - Its superficial location makes its engorgement a clinically observable sign of **jugular venous distension (JVD)**, indicating increased pressure in the right atrium [1]. *Cephalic vein* - The **cephalic vein** is located in the arm and is not directly reflective of **central venous pressure** or right heart function. - While it can be distended in conditions causing peripheral venous congestion, it is not a primary indicator of **heart failure** severity. *Basilic vein* - The **basilic vein** is also located in the arm and, like the cephalic vein, does not provide a direct assessment of **central venous pressure**. - Its distension would reflect more localized or peripheral venous issues rather than systemic heart failure. *Internal jugular vein* - The **internal jugular vein** is directly connected to the right atrium and is the most accurate reflection of **central venous pressure**; however, its pulsations are typically *not* directly visible as a distinct, engorged vein [1]. - Clinicians assess the **internal jugular vein** by observing the pulsations of the sternocleidomastoid muscle, which correspond to changes in its pressure, rather than direct visualization of the vein itself.

Question 1417: A patient with suspected myocardial infarction has a troponin I level of 0.5 ng/mL (normal <0.4 ng/mL). What is the next best step in managing this patient?

A. Discharge with lifestyle modification
B. Repeat troponin in 3 hours
C. Immediate thrombolysis
D. Obtain 12-lead ECG (Correct Answer)

Explanation: ***Obtain 12-lead ECG*** - An elevated **troponin I level** (even if mildly elevated above the normal threshold) in the context of suspected **myocardial infarction** necessitates further investigation to assess for acute cardiac injury [3]. - A **12-lead ECG** is crucial for identifying acute ischemic changes (e.g., **ST-segment elevation or depression**, **T-wave inversions**) which can guide immediate management decisions [1], [2]. *Discharge with lifestyle modification* - Discharging the patient with an elevated **troponin I** without further evaluation would be premature and potentially harmful, as it indicates ongoing myocardial injury. - **Lifestyle modifications** are important for long-term cardiovascular health but are not an immediate management step for acute cardiac symptoms and elevated biomarkers. *Repeat troponin in 3 hours* - While serial troponin measurements are essential for evaluating the **kinetics of cardiac injury**, an initial elevated value requires immediate assessment of the electrical activity of the heart. - Waiting to repeat troponin before getting an **ECG** could delay critical interventions if acute myocardial ischemia is present. *Immediate thrombolysis* - **Thrombolysis** is a treatment reserved for specific scenarios of **ST-elevation myocardial infarction (STEMI)** where percutaneous coronary intervention (PCI) is not immediately available. - Administering thrombolysis based solely on an elevated troponin without an **ECG** confirming STEMI or without consideration of contraindications would be inappropriate and potentially dangerous [2].

Question 1418: In the management of myocardial infarction, which medication has been demonstrated to reduce mortality?

A. Calcium channel blockers (primarily for angina management)
B. Anticoagulants (prevent thrombus formation)
C. ACE inhibitors (Correct Answer)
D. Antiarrhythmic drugs (used for arrhythmias)

Explanation: ***ACE inhibitors*** - **ACE inhibitors** are crucial post-MI, particularly in patients with **ST-elevation myocardial infarction (STEMI)**, anterior infarcts, or those with signs of **heart failure (HF)**, as they improve long-term survival and reduce the risk of remodeling [2]. - They work by inhibiting **angiotensin-converting enzyme**, thereby reducing vasoconstriction, preventing sodium and water retention, and decreasing cardiac preload and afterload. *Calcium channel blockers (primarily for angina management)* - While effective for **symptomatic relief of angina** and **hypertension**, **calcium channel blockers** generally do not reduce mortality post-MI and can be harmful in patients with **left ventricular dysfunction** [1]. - They are primarily used to manage symptoms when **beta-blockers** are contraindicated or ineffective, rather than improving survival directly after an MI [1]. *Anticoagulants (prevent thrombus formation)* - **Anticoagulants** prevent the formation and growth of new thrombi and are vital in the acute phase of MI and for secondary prevention in high-risk patients. - However, their primary role is to **prevent thrombotic events** (like reinfarction or stroke), not directly reduce overall mortality in the same way neurohormonal blockers do. *Antiarrhythmic drugs (used for arrhythmias)* - **Antiarrhythmic drugs** are used to treat or prevent specific **malignant arrhythmias** that can occur post-MI, such as ventricular tachycardia or fibrillation, which are life-threatening. - While they can be life-saving in acute arrhythmic events, widespread prophylactic use of antiarrhythmics has not been shown to reduce overall mortality post-MI and some have been associated with increased mortality.

Question 1419: A 65-year-old woman with atrial fibrillation and a CHA2DS2-VASc score of 4 is being managed with warfarin. What is the target INR range for stroke prevention in this patient?

A. 1.5-2.0
B. 2.0-3.0 (Correct Answer)
C. 2.5-3.5
D. 3.0-4.0

Explanation: ***2.0-3.0*** - For **atrial fibrillation** patients at moderate to high risk of stroke (CHA2DS2-VASc score ≥ 2), a target **INR range of 2.0-3.0** is recommended for stroke prevention with warfarin [1], [2]. - This range provides an optimal balance between reducing **thrombotic risk** and minimizing the risk of **major bleeding** events [1]. *1.5-2.0* - This **INR range** is generally considered **subtherapeutic** for stroke prevention in most patients with atrial fibrillation and would not provide adequate anticoagulation. - It may be appropriate for some specific indications, such as **venous thromboembolism (VTE) prophylaxis** in certain high-risk orthopedic surgeries, but not for atrial fibrillation. *2.5-3.5* - This **INR range** may be considered for patients with **mechanical heart valves** or in specific situations where a higher level of anticoagulation is required due to increased thromboembolic risk despite optimal INR control. - However, for most patients with non-valvular atrial fibrillation, an **INR of 2.0-3.0** is sufficient and safer. *3.0-4.0* - An **INR range** this high is generally associated with a significantly increased risk of **bleeding complications** without providing substantial additional benefit for stroke prevention in most atrial fibrillation patients. - Such high targets are rarely recommended and only in very specific, high-risk scenarios, often under close medical supervision.

Question 1420: A 50-year-old male presents with aortic regurgitation. What would be the characteristic change in the left ventricular pressure-volume loop?

A. Increased preload (Correct Answer)
B. Decreased preload
C. Increased afterload
D. Decreased afterload

Explanation: ***Increased preload*** - In **aortic regurgitation**, blood flows back into the **left ventricle** during diastole, causing an increase in the end-diastolic volume [1]. - This increased volume stretches the ventricular muscle fibers more, leading to a higher **preload**. *Decreased preload* - **Decreased preload** would be seen in conditions like hypovolemia or mitral stenosis, where ventricular filling is reduced. - In aortic regurgitation, the characteristic is an *increase* in end-diastolic volume, directly opposing a decrease in preload. *Increased afterload* - **Increased afterload** typically occurs in conditions like aortic stenosis or hypertension, where the heart has to pump against greater resistance. - While chronic **aortic regurgitation** can lead to some compensatory changes, the primary and most immediate characteristic change in the pressure-volume loop is related to volume overload (preload), not increased resistance to ejection. *Decreased afterload* - **Decreased afterload** would mean less resistance to ventricular ejection, often seen with vasodilators or conditions leading to reduced systemic vascular resistance. - This is the opposite of what happens in **aortic regurgitation**, where the primary hemodynamic burden is volume overload during diastole.

Practice by Chapter

Coronary Artery Disease and Angina

Practice Questions

Acute Coronary Syndromes

Practice Questions

Heart Failure

Practice Questions

Cardiac Arrhythmias

Practice Questions

Valvular Heart Diseases

Practice Questions

Cardiomyopathies

Practice Questions

Pericardial Diseases

Practice Questions

Congenital Heart Disease in Adults

Practice Questions

Hypertension and Hypertensive Emergencies

Practice Questions

Pulmonary Hypertension

Practice Questions

Non-invasive Cardiac Diagnostics

Practice Questions

Preventive Cardiology

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Cardiology — MCQs

Cardiology — MCQs

On this page

Practice by Chapter

Want unlimited practice?